WO2005082878A1 - Hki10311129, neues antibiotikum, verfahren zu dessen herstellung und dessen verwendung - Google Patents
Hki10311129, neues antibiotikum, verfahren zu dessen herstellung und dessen verwendung Download PDFInfo
- Publication number
- WO2005082878A1 WO2005082878A1 PCT/DE2005/000186 DE2005000186W WO2005082878A1 WO 2005082878 A1 WO2005082878 A1 WO 2005082878A1 DE 2005000186 W DE2005000186 W DE 2005000186W WO 2005082878 A1 WO2005082878 A1 WO 2005082878A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibiotic
- hkil
- dsm
- culture
- deposit
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- the vanA-determined vancomycin resistance has so far only occurred in enterococci (NRE), without the extreme multi-resistance problem as in MRSA.
- NRE enterococci
- the long-feared interspecific transfer of vanA resistance from enterococci to staphylococci first occurred in the United States in 2002.
- the vanA gene is integrated in a multi-resistance plasmid (Gott Kunststoff, S. BMJ 326; 783 (2003)).
- the object of the invention is to provide a new microbial active substance with an original structure and good antimicrobial properties, especially against multi-resistant germs.
- HKI10311129 the new antimicrobial agent, hereinafter referred to as HKI10311129, accumulates in the culture broth and then HKI10311129 can be isolated from it in pure form.
- the Streptomyces strain HKI 0179 was deposited in the German Collection for Microorganisms and Cell Cultures (DSMZ) in Braun- schweig, Mascheroder Weg 1, under the name DSM 13059.
- HKI 10311129 differs from the previously known antibiotics by its chemical structure, the novelty of which is undoubtedly proven by physicochemical measurements (Tab. 1 and 2).
- No antimicrobial effects are known of related structures described in Japanese Patent 94,339,395, CA 122, 237919g and J. Antibiot., 45 (1992), 1974-6.
- Another related structure described in J. Antibiot. 51 (1998), 21-25, 26-32, although activity against methicillin-resistant staphylococci is known, but no activity against enterococci, and especially no activity against strains with vanA-determined nancomycin resistance.
- HKI 10311129 Although the antibiotic altamiramycin is already known from the Streptomyces strain DSM 13059 (DE 100 65 606), the new antimicrobial agent HKI 10311129 has now been discovered, which surprisingly has a very strong antibacterial activity against gram-positive bacteria, especially against multi-resistant germs such as staphylococci and enterococci. HKI10311129 can be used specifically as a remedy for infections with multi-resistant gram-positive germs, including those with vanA-determined glycopeptide resistance, in humans and animals.
- the invention thus relates to:
- HKI10311129 the physicochemical characteristics listed in Tables 1 and 2, called HKI10311129.
- the anti-infective compounds can be used as a solution or suspension in pharmaceutically acceptable media for topical or parenteral administration, via intravenous, subcutaneous or intramuscular injections, for intranasal administration, as a tablet, Capsule or suppository can be prepared in doses of 0.1-1000 mg / kg body weight.
- HKIl 0311129 which is characterized in that Streptomyces sp. DSM 13059 cultured in a nutrient medium until HKIl 0311129 accumulates in the culture broth and it is subsequently isolated therefrom. 4.
- HKIl 0311129 as a pharmacologically active substance, in particular as an antibiotic, in particular against multi-resistant and vancomycin-resistant bacteria.
- connection according to the invention is called HKI 10311129.
- the culture broth is the nutrient medium which contains the streptomycete mycelium grown therein.
- the antibiotic HKI10311129 according to the invention is produced by a Streptomyces sp. Strain, an isolate from the "Grotta dei Cervi” in southern Italy. This strain is characterized by specific characteristics (see below).
- Streptomyces sp. DSM 13059 isolated a colony that the antibiotic HKI 10311129 accumulates particularly efficiently in the culture broth.
- An isolate from Streptomyces sp. DSM 13059 was deposited with the German Collection of Microorganisms and Cell Cultures GmbH in Braunschweig, Mascheroder Weg 1B, 38124 Braunschweig, Germany, under the deposit no. 13059 on September 24, 1999 in accordance with the terms of the Budapest Treaty. It can be characterized as follows: LL-DAP in peptidoglycan, spore carriers of type S, open spirals, usually short 34, max.
- variants and mutants can be generated in a manner known per se by physical means, for example irradiation with ultraviolet or X-rays or chemical mutagens.
- the screening for mutants and variants which synthesize the compound according to the invention can be carried out by determining the biological activity of the active compounds accumulated in the culture broth, for example by testing the antibiotic action on known test germs using the methods known to the person skilled in the art and by chromatographic detection.
- asssimilable carbohydrates and sugar alcohols are suitable, e.g. Glucose, lactose, maltose, glycerol, mannitol or their mixtures as well as natural products containing carbohydrates, such as malt extract or molasses.
- Suitable nitrogen sources are amino acids, peptides and proteins and their breakdown products, such as tryptones or peptones, also meat extracts, ground seeds, for example from corn, wheat, beans, soybeans or the cotton plant, distillation residues from alcohol production, fishmeal or yeast extracts.
- the cultivation is carried out aerobically, for example submerged with shaking or stirring in Erlenmeyer flasks or fermenters, if appropriate with the introduction of air or oxygen.
- the fermentation can be carried out, for example, in steep breast bottles, Erlenmeyer or round-bottom flasks of different volumes, in glass fermenters or V 2 A steel tanks.
- the microorganism is cultivated under these conditions for 3 to 6 days.
- the fermentation can be carried out on a laboratory scale (culture volumes between 100 ml and 200 ml), but also on a production scale (volumes up to several m 3 ).
- Cultivation is advantageously carried out in several stages, i.e. First, one or more pre-cultures are prepared in a liquid nutrient medium, which are then inoculated into the actual production medium, the main culture, for example in a ratio of 1:15 - 1:20.
- the preculture is obtained by using a mycelium, e.g. Transferred oatmeal nutrient media into a nutrient solution, for example by inoculating pieces of agar covered with mycelium, and incubated for 1 to 2 days.
- a mycelium e.g. Transferred oatmeal nutrient media into a nutrient solution, for example by inoculating pieces of agar covered with mycelium, and incubated for 1 to 2 days.
- the shipped mycelium can be obtained, for example, by letting the strain grow on a nutrient medium, such as oatmeal agar or soy melamine-glucose agar, for about 7-10 days.
- a nutrient medium such as oatmeal agar or soy melamine-glucose agar.
- the antibiotic HKI10311129 is contained in varying proportions in the culture broth, and preferably in the mycelium.
- Detection in thin-film chiinato graphic separation can be carried out using various staining agents (e.g. vanillin-sulfuric acid).
- staining agents e.g. vanillin-sulfuric acid
- the antibiotic HKI10311129 is isolated from the culture broth and the mycelium by known methods, taking into account the chemical, physical and biological properties of the products.
- the culture medium and mycelium are separated at the end of the fermentation and the mycelium is extracted with organic solvents such as methanol or acetone, preferably methanol.
- Additional amounts of HKI10311129 are obtained by extracting the culture solution separated from the mycelium with water-soluble organic solvents, such as e.g. Ethyl acetate.
- the antibiotic HKI10311129 is isolated using conventional chromatographic adsorbents or carrier materials, such as e.g. Silica gel or organophilic dextran gels.
- the chemical identity of the antibiotic HKIl 0311129 is determined by the results of high-resolution mass spectrometry (FAB-MS, quadrupole electrospray MS, CID-MS / MS) as well as high-resolution 600 MHz proton and 150 MHz I3 C NMR correlation - Spectroscopy, proven.
- the antibacterial effects of HKI10311129 can be determined by methods known to the person skilled in the art, such as, for example, agar plate diffusion test and the determination of the minimum inhibitory concentration (MIC).
- HKI10311129 is against bacteria, preferably against gram-positive bacteria such as e.g. Bacilhis siibtilis ATCC 6633, Staphylococcus aureus SG 511, Staphylococcus aureus 134/93 (multi-resistant) and Enterococcus fa ⁇ calis 1528 (vanA-detected vancomycin resistance) are effective.
- Bacilhis siibtilis ATCC 6633 Staphylococcus aureus SG 511
- Staphylococcus aureus 134/93 multi-resistant
- Enterococcus fa ⁇ calis 1528 vanA-detected vancomycin resistance
- the antibiotic HKI10311129 according to the invention is very well suited for use as an antimicrobial therapeutic, in particular for use against vanA-resistant risk germs, such as vanA-resistant enterococci and in the meantime occurred, miire-resistant and vanA-determined vancomycin-resistant staphylococci.
- the antibiotic HKI10311129 according to the invention can be administered as such in bulk or as a pharmaceutical preparation with suitable auxiliaries or carrier material known to the person skilled in the art.
- the preparation forms are produced in a manner known per se using customary auxiliaries and carriers, such as, for example, in the “Remington's Pharmaceutical Sciences Handbook, Ralph Pub. co., NY, USA ".
- the pharmaceutical preparation forms can be peroral, for example tablets, capsules and dragees, percutaneous preparation forms, for example ointments or sprays, transdermal therapeutic systems (TTS) or gels, for intranasal preparation forms such as Nasal spray or nasal drops, rectal preparation forms such as suppositories and parenterals, for example: implants, pellets and ampoules.
- the medicaments according to the invention are generally administered orally or parenterally, but rectal use is also possible. Suitable solid or liquid galenical preparation forms are possible for example granules, powders, tablets, coated tablets, suspensions.
- the antimicrobial properties were determined according to the US Labor Standard - Methods of the National Committee for Clinical Laboratory Standards (NCCLS) for aerobically growing bacteria in liquid media (National Comittee for Clinical Laboratory Standards, Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, Approved Standard M7 -A.NCCLS, Villanova, Pa., 1991). The determined MIC values are shown in Table 3. Table 1: Physicochemical properties of HKIl 0311129
- Staphylococcus aureus SG 511 0.8 Staphylococcus aureus 134/93 (MRSA) 0.8 Enterococcus faecalis 1528 (VRE) 0.4 Bacillus subtilis ATCC 6633 ⁇ 0.05 Ausfithrungsbeidin
- the culture solution according to Example 1 is separated into mycelium and culture filtrate.
- the former is extracted with methanol.
- the extract is diluted with 4 times the volume of water and extracted with ethyl acetate.
- the culture filtrate is also extracted in a ratio of 2: 1 (aqueous phase to ethyl acetate).
- the ethyl acetate extracts are combined, dried over sodium sulfate and evaporated to dryness in vacuo.
- Chromatographic purification of HKI 10311129 The remaining brown, oily residue is taken up in a little chloroform and the solution is filtered. Raw product is precipitated by adding hexane (20 times its volume).
- the further purification is carried out by gel permeation chromatography on Sephadex LH-20 using methanol as the eluent.
- the middle fraction which has antibacterial activity, is combined and evaporated to dryness in a vacuum.
- the fine purification is carried out by silica gel chromatography using a chloroform-methanol gradient (100: 0; 95: 5; 9: 1).
- the yellow fraction with antibacterial effect is evaporated to dryness.
- High-purity HKI 10311129 can be obtained by chromatography on reverse phase silica gel using a weakly acidic eluent (for example MeCN-H 0; 83:17 and 0.05% trifluoroacetic acid).
- the international depository accepts the microorganism referred to under I, which it received on 1999-09-24 (date of first deposit) 1 .
- microorganism referred to under I has been received by this International Depository on (date of first deposit) and an application for the conversion of this first deposit into a deposit under the Budapest Treaty has been received on (date of receipt of the request for conversion).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE502005001193T DE502005001193D1 (de) | 2004-02-27 | 2005-02-02 | Hki10311129, neues antibiotikum, verfahren zu dessen herstellung und dessen verwendung |
EP05714937A EP1740566B1 (de) | 2004-02-27 | 2005-02-02 | Hki10311129, neues antibiotikum, verfahren zu dessen herstellung und dessen verwendung |
US11/497,953 US7557091B2 (en) | 2004-02-27 | 2005-02-02 | HKI10311129, novel antibiotic, method for producing the same and the use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004010219.8 | 2004-02-27 | ||
DE102004010219A DE102004010219B4 (de) | 2004-02-27 | 2004-02-27 | HKI10311129, neues Antibiotikum, Verfahren zu dessen Herstellung und Arzneimittel enthaltend HKI10311129 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/497,953 Continuation-In-Part US7557091B2 (en) | 2004-02-27 | 2005-02-02 | HKI10311129, novel antibiotic, method for producing the same and the use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005082878A1 true WO2005082878A1 (de) | 2005-09-09 |
Family
ID=34853916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2005/000186 WO2005082878A1 (de) | 2004-02-27 | 2005-02-02 | Hki10311129, neues antibiotikum, verfahren zu dessen herstellung und dessen verwendung |
Country Status (6)
Country | Link |
---|---|
US (1) | US7557091B2 (de) |
EP (1) | EP1740566B1 (de) |
AT (1) | ATE369352T1 (de) |
DE (2) | DE102004010219B4 (de) |
ES (1) | ES2292111T3 (de) |
WO (1) | WO2005082878A1 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005053670B4 (de) * | 2005-11-08 | 2008-01-10 | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. -Hans-Knöll-Institut- | Verfahren zur Spaltung von Cervimycin-Halbestern |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06339395A (ja) * | 1993-04-05 | 1994-12-13 | Mitsubishi Kasei Corp | 新規生理活性物質及びその製造法 |
DE10065606A1 (de) * | 2000-12-26 | 2002-06-27 | Knoell Hans Forschung Ev | Altamiramycin, Verfahren zu dessen Herstellung und dessen Verwendung |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1567456A (en) * | 1976-11-16 | 1980-05-14 | Farmaceutici Italia | Daunomycin derivatives |
DE19635642A1 (de) * | 1996-09-03 | 1998-03-05 | Knoell Hans Forschung Ev | Neue Dihydrobenzo[a]naphthacenchinone, ein Verfahren zu ihrer Herstellung und Verwendung derselben |
DE10155016A1 (de) * | 2001-11-07 | 2003-05-15 | Knoell Hans Forschung Ev | Neue Chinon-Verbindung, Verfahren zur Herstellung und deren Verwendung |
-
2004
- 2004-02-27 DE DE102004010219A patent/DE102004010219B4/de not_active Expired - Fee Related
-
2005
- 2005-02-02 DE DE502005001193T patent/DE502005001193D1/de active Active
- 2005-02-02 ES ES05714937T patent/ES2292111T3/es active Active
- 2005-02-02 US US11/497,953 patent/US7557091B2/en not_active Expired - Fee Related
- 2005-02-02 EP EP05714937A patent/EP1740566B1/de active Active
- 2005-02-02 WO PCT/DE2005/000186 patent/WO2005082878A1/de active IP Right Grant
- 2005-02-02 AT AT05714937T patent/ATE369352T1/de not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06339395A (ja) * | 1993-04-05 | 1994-12-13 | Mitsubishi Kasei Corp | 新規生理活性物質及びその製造法 |
DE10065606A1 (de) * | 2000-12-26 | 2002-06-27 | Knoell Hans Forschung Ev | Altamiramycin, Verfahren zu dessen Herstellung und dessen Verwendung |
Non-Patent Citations (2)
Title |
---|
HEROLD, KERSTIN ET AL: "Biosynthesis of cervimycin C, an aromatic polyketide antibiotic bearing an unusual dimethylmalonyl moiety", ORGANIC & BIOMOLECULAR CHEMISTRY , 2(17), 2411-2414 CODEN: OBCRAK; ISSN: 1477-0520, 2004, XP002336421 * |
PATENT ABSTRACTS OF JAPAN vol. 1995, no. 03 28 April 1995 (1995-04-28) * |
Also Published As
Publication number | Publication date |
---|---|
US7557091B2 (en) | 2009-07-07 |
EP1740566B1 (de) | 2007-08-08 |
ES2292111T3 (es) | 2008-03-01 |
ATE369352T1 (de) | 2007-08-15 |
US20060270617A1 (en) | 2006-11-30 |
DE502005001193D1 (de) | 2007-09-20 |
DE102004010219B4 (de) | 2007-02-01 |
EP1740566A1 (de) | 2007-01-10 |
DE102004010219A1 (de) | 2005-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0629636A1 (de) | Lipopeptide aus Actinoplanes sp. mit pharmakologischer Wirkung, Verfahren zu ihrer Herstellung und Verwendung derselben | |
RU2536587C2 (ru) | Антибиотические соединения | |
AT395860B (de) | Verfahren zur herstellung eines neuen antitumor-antibiotikums und seine verwendung | |
US8183341B2 (en) | Antibacterial compounds and processes for its production | |
KR101764349B1 (ko) | 펩티드 디포밀라제 저해 및 항균 활성을 갖는 신규한 프라비마이신 화합물 | |
DE19920816A1 (de) | Cephaibole, neue Antiparasitika aus Acremonium tubakii, Verfahren zu ihrer Herstellung und Verwendung derselben | |
KR101344083B1 (ko) | 폴리사이클릭 펩타이드 화합물을 포함하는 항균용 조성물 및 이의 생산방법 | |
EP1740566B1 (de) | Hki10311129, neues antibiotikum, verfahren zu dessen herstellung und dessen verwendung | |
RU2261254C2 (ru) | Мемнопептиды, способ их получения и их применение | |
EP1689731B1 (de) | 2-phenyl-benzofuran-derivate, verfahren zur ihrer herstellung und ihre verwendung | |
RU2228337C2 (ru) | Ванкорезмицин (варианты), его использование, штамм amycolatopsis вида hil-006734 для его получения | |
EP0387860A2 (de) | Antitumor-Antibiatika-BMY-41339 | |
DE69913369T2 (de) | Mikrobielle transformationsprodukte | |
EP0848064B1 (de) | Neues Antibiotikum, Feglymycin, Verfahren zu seiner Herstellung und Verwendung | |
KR102342719B1 (ko) | 마이크로모노스포라 속 균주를 유효성분으로 포함하는 항균용 조성물 | |
DE10065606A1 (de) | Altamiramycin, Verfahren zu dessen Herstellung und dessen Verwendung | |
EP0818539A1 (de) | Methylsulfomycin I, Verfahren zu dessen Herstellung und Verwendung | |
DE19948644A1 (de) | Neue Peptaibole mit neuroleptischer Wirkung | |
DE19943460A1 (de) | Neue Lipopeptide und deren Verwendung als Arzneimittel | |
EP1404663A1 (de) | Eurotinone und derivate davon, verfahren zu ihrer herstellung und verwendung derselben | |
JP4755248B2 (ja) | 新規な抗生物質、ビスポライドA1、A2およびA3ならびにビスポライドB1、B2a、B2bおよびB3と、それら抗生物質の製造方法 | |
DE10353300A1 (de) | Polyzyklische Makrolactone | |
DE10238697A1 (de) | Neue Peptaibole mit neuroleptischer Wirkung | |
WO2005033114A1 (de) | Polyzyklische makrolactone | |
DE4305351A1 (de) | Aurantimycin, Peptidantibiotikum aus Streptomyces aurantiacus, und chemische Derivate mit pharmakologischer Wirkung, ein Verfahren zur Herstellung und Verwendung derselben |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005714937 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11497953 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 11497953 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2005714937 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2005714937 Country of ref document: EP |